IP vs RNA · P/E 43, $26.62B cap vs rev $10.9M
International Paper (IP) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
International Paper (IP) is a packaging & containers company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
IP does not have a complete income-statement cache yet.
Latest reported RNA revenue for 2024-12-31 was $10.9M. Net income was -$322.3M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. RNA currently screens at market cap $217.5M.
IP currently screens at market cap $26.62B and trailing P/E 43.1. RNA currently screens at market cap $217.5M.
Not investment advice. Open the IP and RNA stock pages for the full models.
Not investment advice.